Gland Pharma Q2FY27 Results: PAT Surges 58% YoY Driven By CDMO Growth
Gland Pharma Ltd · Press Release · 06 Nov 2026, 10:22 pm
Gland Pharma Q2FY27 Results: PAT Surges 58% YoY Driven By CDMO Growth Gland Pharma reported strong Q2FY27 consolidated performance, with revenue rising 23% YoY to ₹18,336 Mn and PAT surging 58% YoY to ₹2,908 Mn, expanding PAT margins by ~350 bps YoY to 16%. Adjusted EBITDA increased 50% YoY to ₹5,030 Mn with a 27% margin. Growth was led by the CDMO segment (+31% YoY to ₹8,227 Mn) and core US markets (+42% YoY to ₹11,795 Mn). R&D stood at ₹1,077 Mn (6% of revenue). In quality audits, USFDA cleared VSEZ with zero observations and Dundigal with four procedural observations.
Original exchange filing (PDF)
More announcements from Gland Pharma Ltd
- Schedule of Investor Meet Intimation · 17 Nov 2026
- Allotment of 3739 Equity Shares on exercise of ESOPs · 16 Nov 2026
- Grant of Options to Purchase Securities · 16 Nov 2026
- Q2FY27 Earnings Call Transcript · 12 Nov 2026
- Gland Pharma Limited has issued Corporate Guarantee on behalf of Phixen SAS, wholly owned step down subsidiary of the Company · 12 Nov 2026
- Appointment of Mr. Xiao Le as Chief Investment Officer at Gland Pharma International Pte. Ltd, wholly owned subsidiary of Gland Pharma Limited, effective November 09, 2026 · 09 Nov 2026
- Q2FY27 Earnings Call Recording · 07 Nov 2026
- Q2Fy27 Investors presentation · 06 Nov 2026
